Literature DB >> 24535609

Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer.

Mehmet Ali Nahit Şendur1, Dogan Uncu, Nurullah Zengin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24535609     DOI： 10.1007/s12032-014-0890-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  10 in total

1.  Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

Authors:  G Metro; J Foglietta; M Russillo; L Stocchi; A Vidiri; D Giannarelli; L Crinò; P Papaldo; M Mottolese; F Cognetti; A Fabi; S Gori
Journal:  Ann Oncol       Date:  2010-08-19       Impact factor: 32.976

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

4.  Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

Authors:  Nancy U Lin; Wolfgang Eierman; Richard Greil; Mario Campone; Bella Kaufman; Klaudia Steplewski; Stephen R Lane; Denise Zembryki; Stephen D Rubin; Eric P Winer
Journal:  J Neurooncol       Date:  2011-06-26       Impact factor: 4.130

5.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Authors:  Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

6.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

8.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.

Authors:  Shaheenah Dawood; Kristine Broglio; Aman U Buzdar; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

9.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316
  10 in total
  2 in total

1.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

2.  Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.

Authors:  Tori B Terrell-Hall; Mohamed Ismail Nounou; Fatema El-Amrawy; Jessica I G Griffith; Paul R Lockman
Journal:  Oncotarget       Date:  2017-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.